Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 14

1 276 clinical trials
446 recruiting
379 conditions
28 countries

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

1 276 clinical trials

Non-small cell lung cancer+2

Recruiting

Registered drugNo placebo

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Hungary

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Maia Biotechnology Inc.

Contact Research Centre

Respiratory syncytial virus infection

Recruiting

Registered drugNo placebo

Study of RSVPreF3 vaccine with AS01E adjuvant in adults aged 60-65 and over 80 years to prevent respiratory syncytial virus infection

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:Karolinska Institutet

Contact Research Centre

Non-small cell lung cancer+5

Recruiting

Registered drugNo placebo

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Qilu Pharmaceutical Co. Ltd.

Contact Research Centre

Respiratory syncytial virus infection

Recruiting

Registered drugNo placebo

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Lung neoplasm malignant

Recruiting

InvestigationalNo placebo

Comparing Lung Perfusion PET/CT-Guided Versus Standard Planning for Stereotactic Body Radiotherapy in Patients with Primary or Secondary Lung Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gallium (68Ga)
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

COVID-19

Recruiting

Registered drugNo placebo

Study of Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients with No or Mild Symptoms

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Remdesivir
Sponsor:Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia

Contact Research Centre

Pulmonary hypertension

Recruiting

Registered drugNo placebo

Testing the safety of stopping riociguat in patients with chronic thromboembolic pulmonary hypertension after successful balloon pulmonary angioplasty treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Riociguat
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Rhinitis allergic+1

Recruiting

Investigational

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational

Spain

Participants:0–17 years · 18–64 years
Substances:Sodium Chloride
Sponsor:Advanced Outcomes Research S.L.

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Registered drug

Study of MTX-463 compared to placebo to assess its safety and effectiveness in adults with idiopathic pulmonary fibrosis

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Glucose Monohydrate
Sponsor:Mediar Therapeutics Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Registered drug

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacion GECP

Contact Research Centre

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trials Pembrolizumab145 clinical trials Cisplatin128 clinical trials Pemetrexed108 clinical trials Paclitaxel80 clinical trials Durvalumab71 clinical trials Atezolizumab50 clinical trials Nivolumab49 clinical trials Sodium Chloride49 clinical trials

Respiratory, thoracic and mediastinal disorders – page 14

Conditions in this area

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 clinical trials

Non-small cell lung cancer+2

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Respiratory syncytial virus infection

Study of RSVPreF3 vaccine with AS01E adjuvant in adults aged 60-65 and over 80 years to prevent respiratory syncytial virus infection

Non-small cell lung cancer+5

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Non-small cell lung cancer

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Respiratory syncytial virus infection

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Lung neoplasm malignant

Comparing Lung Perfusion PET/CT-Guided Versus Standard Planning for Stereotactic Body Radiotherapy in Patients with Primary or Secondary Lung Tumors

COVID-19

Study of Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients with No or Mild Symptoms

Pulmonary hypertension

Testing the safety of stopping riociguat in patients with chronic thromboembolic pulmonary hypertension after successful balloon pulmonary angioplasty treatment

Rhinitis allergic+1

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Idiopathic pulmonary fibrosis

Study of MTX-463 compared to placebo to assess its safety and effectiveness in adults with idiopathic pulmonary fibrosis

Chronic obstructive pulmonary disease

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Non-small cell lung cancer

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.